Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1101221083
Ticker BMY
Company BRISTOL-MYERS SQUIBB
Currency $
Price
Aware Investor Index (AII) 3.4520
Recommendation BUY
P/E 27.64
ROE 20.19 %
Capitalization 78,837,920,000 $
Dividend Yield 3.34 %
P/S 3.49
AII Position 168
P/E Position 416
ROE Position 161
Capitalization Position 110
Dividend Yield Position 205
Sales 22,561,000,000 $
10-Year Average Earnings 2,852,600,000 $
Shares Outstanding 1,637,000,000
Equity 14,127,000,000 $
Dividend per Share 1.61 $
Industry Pharmaceutical
Country United States
BRISTOL-MYERS SQUIBB Investor Relations Web Site https://www.bms.com/investors.html







Sales:

YEAR MONTH AMOUNT
2018 12 22,561,000,000.00 $
2017 12 20,776,000,000.00 $
2016 12 19,427,000,000.00 $
2015 12 16,560,000,000.00 $
2014 12 15,879,000,000.00 $
2013 12 16,385,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 4,920,000,000.00 $
2017 12 1,007,000,000.00 $
2016 12 4,457,000,000.00 $
2015 12 1,565,000,000.00 $
2014 12 2,004,000,000.00 $
2013 12 2,563,000,000.00 $
2012 12 1,960,000,000.00 $
2011 12 3,709,000,000.00 $
2010 12 3,102,000,000.00 $
2009 12 3,239,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 14,127,000,000.00 $
2017 12 11,847,000,000.00 $
2016 12 16,347,000,000.00 $
2015 12 14,424,000,000.00 $
2014 12 14,983,000,000.00 $
2013 12 15,236,000,000.00 $
2012 12 13,638,000,000.00 $
2011 12 15,867,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,785,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 1,637,000,000
2017 12 1,652,000,000
2016 12 1,680,000,000
2015 12 1,679,000,000
2014 12 1,670,000,000
2013 12 1,662,000,000
2012 12 1,688,000,000
2011 12 1,717,000,000
2010 12 1,727,000,000
2009 12 1,978,000,000

 












Bloomberg News for BRISTOL-MYERS SQUIBB:



Google News for BRISTOL-MYERS SQUIBB:

MONReport - 2 days ago
A Value Play In An Overlooked Sector: Bristol-Myers Squibb ...
Wall Street analysts will be watching closely when Bristol-Myers Squibb Company (NYSE:BMY) reports its quarterly earnings next, which is ...
Zacks.com
Bristol-Myers Squibb Company (NYSE:BMY) Analyst's Long Term ...
Bristol-Myers Squibb Company (NYSE:BMY) has been recommended as a long term growth pick according to Beta Research. With their stock ...
StreetInsider.com
Bristol-Myers Squibb Company (BMY) Price Is Up By 0.14 ...
At the moment, the debt-to-equity of Bristol-Myers Squibb Company (NYSE:BMY) is high, standing at 52.38, a figure that is higher than the ...
The RNS Daily
Bristol-Myers Squibb Company (BMY) Management Presents at ...
Bristol-Myers Squibb Company (NYSE:BMY) Barclays 2019 Global Healthcare Conference Call March 13, 2019 12:30 PM ET. Company ...
Herdon Gazette - 8 hours ago
For Bristol-Myers Squibb's Sake, Celgene Merger Should Be Voted ...
For Bristol-Myers Squibb's Sake, Celgene Merger Should Be Voted Down ... deal has more to do with Celgene than with Bristol-Myers Squibb.
The EN Bulletin
If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?
The proposition that there are acquirers who want to own Bristol-Myers Squibb (BMY) at a notably higher price than the current $52-53 trading ...
News Leading (press release)
Bristol-Myers Squibb Company (NYSE:BMY) Valuation in the Spotlight
Bristol-Myers Squibb Company (NYSE:BMY) has an ERP5 rank of 4954. The ERP5 Rank is an investment tool that analysts use to discover ...
Thorold News
Bristol-Myers Squibb: Caforio Makes A Strong Showing At The ...
Bristol-Myers Squibb (BMY) CEO Giovanni Caforio is showing tremendous commitment to the deal with Celgene (CELG) as he's touring all ...
CryptoAmber - 6 days ago
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardy ...
Watch Bristol-Myers Squibb and Celgene trade live. ... to accept too much risk and the terms offer BMY shares to CELG shareholders at a price ...
The RNS Daily
Valuation Does Not Reflect The Risks: Bristol-Myers Squibb ...
Shares of Bristol-Myers Squibb Company (NYSE:BMY) have generated a 1-year price change of -21.32%. However, a year is a very long time ...


Back